Novartis: completes acquisition of CAR-T cell therapy firm
(CercleFinance.com) - Novartis said it has now completed the acquisition of Endocyte, a US-based biopharmaceutical company focused on CAR-T therapies for cancer treatment.
The Swiss drugmaker said the acquisition will add an experimental therapy in Phase III development for metastatic castration-resistant prostate cancer, while strengthening its portfolio of nuclear medicines and radioligand therapies for treating cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Swiss drugmaker said the acquisition will add an experimental therapy in Phase III development for metastatic castration-resistant prostate cancer, while strengthening its portfolio of nuclear medicines and radioligand therapies for treating cancer.
Copyright (c) 2018 CercleFinance.com. All rights reserved.